Clinical Laserthermia Systems

Clinical Laserthermia Systems Announces Agreement with Kearney Urology Center PC to Treat Prostate Cancer Patients with TRANBERG Thermal Therapy System

REG

 

Under the agreement, CLS provides its FDA 510(k) cleared TRANBERG Thermal Therapy System in a bundled service offering, with consumable accessories, training, and on-site clinical and technical staff support to Kearney Urology physicians and staff during procedures. The Kearney Urology Center PC provides Pediatric and Adult Urologic Care featuring Board Certified Urologists and Robotic Surgery Specialists.

 

“CLS Americas is pleased to provide the Kearney Urology Center, PC with the training, use, and clinical support of our TRANBERG focal laser ablation system,” stated Michael Magnani, president of CLS Americas. “We are excited to be partnering with an emerging regional provider of advanced urological treatments and an early adopter of promising new medical devices and treatments.”

 

"With our full-service agreement, CLS reduces the business risk for the urology practice and offers a good deal for both our customer and CLS. With the increased interest among urology practices in our service offering, more and more prostate cancer patients can be treated with targeted minimally invasive prostate tumor ablation, performed using our TRANBERG system, at a faster pace", says Dan J Mogren, CEO of CLS AB.

 

 

For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com

 

 

About Kearney Urology Center PC

For more information, visit: Kearney Urology Center PC | Pediatrics | Kearney, NE

 

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.

For more information about CLS, please visit the Company's website: clinicallaser.se.

Datum 2023-10-24, kl 13:00
Källa Cision
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!